187 related articles for article (PubMed ID: 25139532)
1. Preoperative chemoradiation therapy for esophageal cancer is a risk factor for the elevation of high mobility group box-1, leading to an increase in postoperative severe pulmonary complications.
Takahata R; Ono S; Tsujimoto H; Hiraki S; Aosasa S; Yamamoto J; Hase K
Dis Esophagus; 2016 Jan; 29(1):70-8. PubMed ID: 25139532
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery?
Suda K; Kitagawa Y; Ozawa S; Saikawa Y; Ueda M; Abraham E; Kitajima M; Ishizaka A
Dis Esophagus; 2006; 19(1):5-9. PubMed ID: 16364036
[TBL] [Abstract][Full Text] [Related]
3. Impact of perioperative high mobility group box chromosomal protein 1 expression on long-term outcomes in patients with esophageal squamous cell carcinoma.
Tsujimoto H; Horiguchi H; Takahata R; Ono S; Yaguchi Y; Nomura S; Ito N; Harada M; Nagata H; Ishibashi Y; Kouzu K; Tsuchiya S; Itazaki Y; Fujishima S; Kishi Y; Ueno H
J Gastroenterol Hepatol; 2020 May; 35(5):788-794. PubMed ID: 31498489
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
[TBL] [Abstract][Full Text] [Related]
5. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
[TBL] [Abstract][Full Text] [Related]
6. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Saeki H; Nakashima Y; Zaitsu Y; Tsuda Y; Kasagi Y; Ando K; Imamura Y; Ohgaki K; Ito S; Kimura Y; Egashira A; Oki E; Morita M; Maehara Y
Surg Today; 2016 Mar; 46(3):261-7. PubMed ID: 25740123
[TBL] [Abstract][Full Text] [Related]
7. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.
Cho WK; Oh D; Kim HK; Ahn YC; Noh JM; Shim YM; Zo JI; Choi YS; Sun JM; Lee SH; Ahn MJ; Park K; Nam H
Radiother Oncol; 2019 Apr; 133():87-92. PubMed ID: 30935586
[TBL] [Abstract][Full Text] [Related]
9. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
[TBL] [Abstract][Full Text] [Related]
11. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer.
Maeda Y; Takeuchi H; Matsuda S; Okamura A; Fukuda K; Miyasho T; Nakamura R; Suda K; Wada N; Kawakubo H; Kitagawa Y
Esophagus; 2020 Jul; 17(3):279-288. PubMed ID: 31845119
[TBL] [Abstract][Full Text] [Related]
13. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
14. Postoperative serum concentrations of high mobility group box chromosomal protein-1 correlates to the duration of SIRS and pulmonary dysfunction following gastrointestinal surgery.
Takahata R; Ono S; Tsujimoto H; Hiraki S; Kimura A; Kinoshita M; Miyazaki H; Saitoh D; Hase K
J Surg Res; 2011 Sep; 170(1):e135-40. PubMed ID: 21696758
[TBL] [Abstract][Full Text] [Related]
15. Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer.
Inoue J; Ono R; Makiura D; Kashiwa-Motoyama M; Miura Y; Usami M; Nakamura T; Imanishi T; Kuroda D
Dis Esophagus; 2013 Jan; 26(1):68-74. PubMed ID: 22409435
[TBL] [Abstract][Full Text] [Related]
16. A review of the impact of preoperative chemoradiotherapy on outcome and postoperative complications in esophageal cancer patients.
Wilke TJ; Bhirud AR; Lin C
Am J Clin Oncol; 2015 Aug; 38(4):415-21. PubMed ID: 24351783
[TBL] [Abstract][Full Text] [Related]
17. Randomized Controlled Study to Evaluate the Efficacy of a Preoperative Respiratory Rehabilitation Program to Prevent Postoperative Pulmonary Complications after Esophagectomy.
Yamana I; Takeno S; Hashimoto T; Maki K; Shibata R; Shiwaku H; Shimaoka H; Shiota E; Yamashita Y
Dig Surg; 2015; 32(5):331-7. PubMed ID: 26183420
[TBL] [Abstract][Full Text] [Related]
18. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
19. Relationship between secretory leukocyte protease inhibitor levels in bronchoalveolar lavage fluid and postoperative pulmonary complications in patients with esophageal cancer.
Tsukada K; Miyazaki T; Katoh H; Masuda N; Ojima H; Fukuchi M; Manda R; Fukai Y; Nakajima M; Sohda M; Kuwano H
Am J Surg; 2005 Apr; 189(4):441-5. PubMed ID: 15820457
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Rather than Pathological Response to Preoperative Chemoradiotherapy Is a Stronger Predictor of Survival in cStage IIB-IV Esophageal Cancer.
Motoyama S; Sato Y; Maruyama K; Usami S; Yoshino K; Nakatsu T; Sasaki T; Wakita A; Kawakita Y; Liu J; Anbai A; Ishiyama K; Saito H; Minamiya Y
Anticancer Res; 2017 Aug; 37(8):4189-4194. PubMed ID: 28739705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
